Fulcrum Therapeutics Inc (NAS:FULC)
$ 7.47 -0.03 (-0.4%) Market Cap: 464.29 Mil Enterprise Value: 238.89 Mil PE Ratio: 0 PB Ratio: 1.97 GF Score: 48/100

Fulcrum Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 02:00PM GMT
Release Date Price: $8.42 (-3.88%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, I'm one of the biotech analysts here at Morgan Stanley. Pleased to have Fulcrum with us for the next session.

Just briefly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So with that, out of the way, we can get going. Happy to have Bryan Stuart, the CEO of Fulcrum with us.

Bryan, maybe just to kick it off before we get into the program, just talk about the platform at Fulcrum and how you're generating targets there?

Bryan E. Stuart
Fulcrum Therapeutics, Inc. - President, CEO & Director

Yes, absolutely. So thanks, everyone, for joining us. So Fulcrum started about 6 years ago, really around the idea of looking to find disease-modifying therapies

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot